-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
70kDa dextran has the potential to better target KRAS
Figure 1 70kDa Dextran has more significant KRAS targeting (A: 4kDa Dextran, B: 70kDa Dextran, C: 150kDa Dextran)
Conjugation of drugs to dextran enhances selectivity of drug delivery to KRAS-mutant cancer cells
Figure 2 DEX-TP enhances the toxicity against KRAS mutant pancreatic cancer cells and the ability to inhibit tumor growth
DEX-TP effectively inhibits the progression of orthotopic pancreatic tumorsFigure 3.
DEX-TP increases the inhibition of pancreatic orthotopic MIAPaCa-2 tumor growth
DEX-TP increases the inhibition of pancreatic orthotopic MIAPaCa-2 tumor growth
DEX-TP prolongs survival in KPC-transplanted mice and alleviates the immune depletion of TP
Figure 4 Therapeutic effect of DEX-TP on KPC xenograft orthotopic tumor model
Challenges and Prospects